logo-loader

CytRx sells remaining stake in RXi Pharmaceuticals for $7 million

Last updated: 01:10 13 Jan 2011 GMT, First published: 02:10 13 Jan 2011 GMT

no_picture_pai

CytRx Corp. (Nasdaq: CYTR), a company specializing in making cancer-related drugs, said today it has sold its remaining shares in RXi Pharmaceuticals (NASDAQ: RXII) for $7 million.

The sale proceeds, CytRx said, will be used to fund the company's batch of upcoming clinical trials.  No further details on the sale were disclosed.

CytRx first gained a stake in RXi Pharmaceuticals in 2007 when it transferred its RNA business to the company.  Shortly after, CytRx began divesting its stake in RXi in 2008, distributing about 36% of RXi shares to its shareholders as a dividend, and has since continued to divest in increments.

CytRx's Bafetinib drug is undergoing Phase 2 clinical trials as a treatment for chronic lymphoid leukemia, the most common type of leukemia, as well as for advanced prostate and brain cancer.

The company's  pipeline also includes Tamibarotene, which is undergoing a Phase 1 trial for the treatment of lung cancer.

RXi Pharmaceuticals' shares dropped 2.4% on the news to close at $2.42 on Wednesday, while CytRx gained almost 5% to close at roughly 92 cents.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

2 hours, 5 minutes ago